TESARO, Inc. (TSRO) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TESARO Announces Third-Quarter 2014 Operating Results
November 5, 2014 4:01 PM ESTOral Rolapitant New Drug Application (NDA) Accepted for Review by U.S. FDA Enrollment in Niraparib NOVA Trial Non-gBRCA Cohort on Track to Be Complete at Year End Anti-LAG-3 Clinical Lead Antibody Identified Cash and Cash Equivalents Totaled Approximately $296 Million as of September 30, 2014
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today reported financial results for the third quarter of 2014.
"We are very pleased... More
